AOD-9604 vs HGH Fragment 176-191
Both are derived from the fat-burning region of human growth hormone but differ in molecular modifications, stability, and research depth. AOD-9604 has more clinical trial data while HGH Frag is the unmodified lipolytic fragment.
Last updated: 2026-03-08
AOD-9604 and HGH Fragment 176-191 are two closely related peptides that both derive from the lipolytic (fat-burning) region of human growth hormone — specifically amino acids 176-191 of the GH molecule. Despite sharing this origin, they are distinct compounds with meaningful differences in molecular structure, research history, and clinical development.
AOD-9604 (Anti-Obesity Drug 9604) is a modified version of this fragment, engineered by Metabolic Pharmaceuticals in Australia with a tyrosine residue added to improve stability and bioactivity. HGH Fragment 176-191 is the unmodified C-terminal fragment of growth hormone, retaining the native amino acid sequence.
Both peptides have been researched for their ability to stimulate lipolysis (fat breakdown) without the diabetogenic or growth-promoting effects of full-length growth hormone. This comparison examines the evidence for each compound.
**Important Note:** Neither AOD-9604 nor HGH Fragment 176-191 is approved for weight loss by the MHRA, EMA, or FDA. This comparison is for educational purposes based on published research.
Quick Comparison Table
| Category | AOD-9604 | HGH Fragment 176-191 |
|---|---|---|
| Origin | Modified C-terminal fragment of GH (aa 176-191 + Tyr) | Unmodified C-terminal fragment of GH (aa 176-191) |
| Molecular Weight | ~1817 Da | ~1815 Da |
| Primary Mechanism | β3-adrenergic receptor-mediated lipolysis | β3-adrenergic receptor-mediated lipolysis |
| Research Focus | Obesity, fat metabolism, cartilage repair | Fat metabolism, body recomposition |
| Clinical Trials | Phase IIb completed (Metabolic Pharmaceuticals) | No formal clinical trials |
| Half-Life | Estimated 30-60 minutes | Estimated 15-30 minutes |
| Oral Bioavailability | No (injection required) | No (injection required) |
| Regulatory Status (UK) | TGA-listed in Australia for health products; research compound in UK | Research compound only |
How They Work: Mechanism of Action
AOD-9604
AOD-9604 Mechanism:
AOD-9604 is the modified C-terminal fragment of human growth hormone with an added tyrosine residue at the N-terminus. Its lipolytic mechanism operates through several pathways:
1. **β3-Adrenergic Receptor Activation** AOD-9604 stimulates lipolysis through β3-adrenergic receptor signalling in adipose tissue, mimicking the fat-burning effects of full growth hormone without activating IGF-1 pathways.
2. **Lipase Stimulation** The peptide activates hormone-sensitive lipase (HSL) in adipocytes, promoting the breakdown of stored triglycerides into free fatty acids and glycerol.
3. **Anti-Lipogenic Effects** AOD-9604 inhibits lipogenesis (new fat formation) by reducing the activity of enzymes involved in fatty acid synthesis, including acetyl-CoA carboxylase.
4. **No IGF-1 Elevation** Critically, AOD-9604 does not raise IGF-1 levels or produce growth-promoting effects, making it more targeted than full GH for fat loss applications.
5. **Cartilage Repair Properties** More recent research has identified potential chondroprotective effects, with AOD-9604 showing promise for osteoarthritis through stimulation of proteoglycan synthesis.
HGH Fragment 176-191
HGH Fragment 176-191 Mechanism:
HGH Fragment 176-191 is the unmodified C-terminal portion of human growth hormone, retaining the native sequence responsible for GH's lipolytic activity:
1. **β3-Adrenergic Receptor Activation** Like AOD-9604, HGH Frag stimulates lipolysis through β3-adrenergic receptor pathways in white adipose tissue, promoting fat mobilisation.
2. **Hormone-Sensitive Lipase Activation** The fragment activates HSL to break down stored triglycerides, similar to the lipolytic action of full-length GH but without the growth-promoting effects.
3. **Inhibition of Lipogenesis** HGH Frag inhibits de novo lipogenesis, reducing the conversion of carbohydrates and other substrates into new fat stores.
4. **No Diabetogenic Effects** Unlike full-length growth hormone, the fragment does not impair glucose metabolism or insulin sensitivity, making it theoretically safer for metabolic research.
5. **Direct Adipocyte Effects** The peptide acts directly on adipocyte receptors without requiring conversion to IGF-1, providing a more targeted mechanism for fat metabolism research.
Clinical Trial Evidence
AOD-9604 Clinical Studies
Participants: 300
Duration: 24 weeks
Statistically significant fat loss vs placebo in obese subjects; well-tolerated with no serious adverse events
Largest clinical trial of any GH-derived fat loss peptide
Participants: 51
Duration: 12 weeks
Dose-dependent increase in fat oxidation; optimal response at 1mg/day oral formulation
Established dose-response relationship in humans
Participants: In vitro + animal
Duration: 8 weeks
Stimulated proteoglycan and collagen synthesis in human chondrocytes; improved cartilage repair in rat OA model
Expanded application beyond fat loss to joint health
Participants: 150
Duration: 12 weeks
No effect on IGF-1, glucose, or insulin levels; safety profile comparable to placebo
Confirmed metabolic safety of GH-fragment approach
Participants: 24
Duration: Single dose + 4 weeks
Oral formulation showed measurable plasma levels; bioavailability lower than injection but clinically relevant
Explored oral administration feasibility
HGH Fragment 176-191 Clinical Studies
Participants: In vitro
Duration: Acute exposure
HGH Fragment 176-191 stimulated lipolysis in murine adipocytes at concentrations 10-100x lower than full GH
Identified the lipolytic region of GH molecule
Participants: Animal (mice)
Duration: 30 days
Significant reduction in body fat without change in IGF-1 or lean mass; no diabetogenic effects
Confirmed fat-specific effects without growth promotion
Participants: In vitro/Animal
Duration: 21 days
Fragment inhibited lipogenesis by 50% in adipose tissue explants; reduced adipocyte size in vivo
Demonstrated dual mechanism: lipolysis + anti-lipogenesis
Participants: Animal (rats)
Duration: 28 days
No effect on blood glucose, insulin sensitivity, or bone growth markers at lipolytic doses
Confirmed separation of lipolytic from diabetogenic effects
Participants: In vitro
Duration: Acute exposure
Fragment matched full GH lipolytic potency but did not activate JAK2/STAT5 growth signalling
Mechanistic confirmation of targeted fat-burning without growth effects
Benefits Comparison
AOD-9604 Unique Benefits
- Human clinical trial data (Phase IIb completed with 300+ subjects)
- Demonstrated oral bioavailability in some formulations
- Additional cartilage repair/chondroprotective properties identified
- TGA-listed in Australia as an approved ingredient in health products
- Better stability profile due to tyrosine modification
- More extensive safety data from controlled human trials
Shared Benefits
- Stimulate lipolysis without IGF-1 elevation or growth effects
- No diabetogenic effects (unlike full-length GH)
- Target adipose tissue specifically
- Inhibit lipogenesis (new fat formation)
- Do not affect lean muscle mass or bone growth
- Generally well-tolerated in research settings
HGH Fragment 176-191 Unique Benefits
- Native GH sequence — no synthetic modifications
- Potent lipolytic activity at very low concentrations
- Simpler molecular structure — easier to synthesise
- Well-characterised mechanism as part of GH research
- Lower cost due to simpler synthesis
- Foundational research that led to AOD-9604 development
Research & Evidence
AOD-9604 Research
AOD-9604 Research Evidence:
AOD-9604 was developed by Metabolic Pharmaceuticals Ltd in Melbourne, Australia, specifically as an anti-obesity therapeutic derived from growth hormone.
Key Research Areas:
Obesity/Fat Loss - Phase IIb clinical trial with 300 obese subjects showed statistically significant fat loss - Dose-dependent effects on fat oxidation established - No effects on IGF-1, glucose metabolism, or insulin sensitivity
Cartilage Repair - More recent research shows chondroprotective effects - Stimulates proteoglycan and collagen synthesis in cartilage cells - TGA-listed in Australia for health products (topical/oral joint formulations)
Safety - Extensive human safety data from clinical trials - No serious adverse events in controlled studies - FDA GRAS (Generally Recognised As Safe) designation for food use
Limitations: - Phase III trials were not completed (company funding issues, not safety concerns) - Most fat loss data is from early 2000s - Cartilage repair research is still early-stage
HGH Fragment 176-191 Research
HGH Fragment 176-191 Research Evidence:
HGH Fragment 176-191 research is primarily preclinical, originating from fundamental growth hormone biology studies.
Key Research Areas:
Lipolysis Mechanism - Identified as the specific region of GH responsible for fat metabolism - Potent lipolytic activity demonstrated in multiple in vitro models - Acts through β3-adrenergic receptor pathway
Animal Studies - Significant fat reduction in obese mouse models - No effects on blood glucose, insulin, or IGF-1 - Selective fat reduction without lean mass changes
Mechanistic Studies - Confirmed separation of GH's lipolytic and growth-promoting activities - Dual mechanism: stimulates lipolysis AND inhibits lipogenesis
Limitations: - No human clinical trials conducted - All evidence is preclinical (in vitro and animal) - Stability and half-life are limited compared to AOD-9604 - Less commercially developed
Head-to-Head Analysis
Direct Comparison:
AOD-9604 is essentially an improved version of HGH Fragment 176-191, so direct comparison reflects an evolution rather than a competition.
Evidence Quality: - AOD-9604 has Phase IIb human clinical trial data — significantly stronger evidence - HGH Fragment has foundational preclinical data that informed AOD-9604's development - Neither has completed Phase III trials
Key Difference: AOD-9604's tyrosine modification provides improved stability and potentially enhanced receptor binding compared to the unmodified fragment. This modification was specifically engineered to create a more viable therapeutic candidate.
Practical Consideration: HGH Fragment 176-191 is more widely available in the research peptide market and is typically less expensive, but lacks the clinical validation of AOD-9604.
Protocol Comparison
AOD-9604 Protocol
AOD-9604 Theoretical Protocols (Research-Based):
Dosing: Clinical trials used oral doses of 0.25-1mg/day. Injectable research doses commonly cited are 250-500 mcg/day. No established therapeutic dose.
Routes: - Subcutaneous injection (most common in research) - Oral administration (explored in clinical trials with lower bioavailability)
Duration: Clinical trials ran 12-24 weeks. No established human protocol duration.
Timing: Often administered in the morning on an empty stomach to maximise lipolytic effect during fasting state.
⚠️ Disclaimer: These are extrapolations from research data. No approved protocols exist.
HGH Fragment 176-191 Protocol
HGH Fragment 176-191 Theoretical Protocols (Research-Based):
Dosing: No human dosing data exists. Commonly cited research doses are 250-500 mcg/day, extrapolated from animal studies and AOD-9604 clinical data.
Routes: - Subcutaneous injection only - Not orally bioavailable
Duration: No established duration. Commonly discussed as 8-12 week research cycles.
Timing: Typically administered pre-fasting or before exercise to capitalise on lipolytic window. Short half-life may require twice-daily dosing.
⚠️ Disclaimer: No human clinical data exists for HGH Fragment 176-191 dosing.
Combined Use
Theoretical Combined Use:
Combining AOD-9604 and HGH Fragment 176-191 is generally not considered useful as they target the same receptor pathway — the β3-adrenergic lipolytic mechanism.
Rationale Against Combination: - Both derive from the same region of GH and act on the same receptors - Combining would likely produce receptor competition rather than synergy - No theoretical or practical basis for additive effects
Alternative Combinations: Researchers more commonly explore pairing either peptide with complementary fat loss compounds targeting different pathways (e.g., GLP-1 agonists, thyroid peptides).
⚠️ Combined use has no scientific basis and is not recommended.
Safety Profiles
AOD-9604 Safety
AOD-9604 Safety Profile:
Clinical Trial Data: - Phase IIb trial: safety profile comparable to placebo - No serious adverse events in 300+ human subjects - No effects on blood glucose, insulin, or IGF-1 levels - FDA GRAS designation for food use
Potential Concerns: - Long-term effects beyond 24 weeks unknown - Limited post-market surveillance data - Quality control varies for research-grade sources
Reported Side Effects: - Injection site reactions (mild, transient) - Headache (uncommon) - Generally very well tolerated
Regulatory: TGA-listed in Australia. Research compound in UK/EU. Not approved for weight loss anywhere.
HGH Fragment 176-191 Safety
HGH Fragment 176-191 Safety Profile:
Preclinical Data: - Well-tolerated in animal studies at lipolytic doses - No diabetogenic effects observed - No effects on growth markers or IGF-1
Potential Concerns: - No human safety data available - Shorter half-life may lead to inconsistent plasma levels - Quality and purity of research sources vary widely - Unknown long-term effects
Theoretical Side Effects: - Injection site reactions - Potential for transient hypoglycaemia (not observed in animal studies)
Regulatory: Research compound only. Not approved for human use in any jurisdiction. WADA prohibited substance.
The Verdict: When to Choose Which?
Choose AOD-9604 When:
- When evidence quality matters — AOD-9604 has Phase IIb human clinical trial data
- When cartilage repair or joint health is also a research interest
- When stability and longer half-life are important considerations
- When a more commercially validated compound is preferred
- When oral administration is being explored as a route
Choose HGH Fragment 176-191 When:
- When studying the native GH lipolytic mechanism without synthetic modifications
- When budget constraints favour a simpler, less expensive peptide
- When foundational mechanistic research is the priority
- When the unmodified GH fragment sequence is specifically required
Consider Combining When:
- Combination is generally not recommended — both target the same pathway
- Would likely produce receptor competition rather than synergy
- No research supports combining these two fragments
- Consider pairing either with complementary-mechanism peptides instead
Frequently Asked Questions
Conclusion
AOD-9604 and HGH Fragment 176-191 represent two generations of the same concept — isolating the fat-burning capability of growth hormone from its growth-promoting and diabetogenic effects. AOD-9604 is the clear leader in terms of evidence, with Phase IIb human clinical data, improved molecular stability, and additional chondroprotective properties. HGH Fragment 176-191 is the foundational molecule that inspired AOD-9604's development and remains relevant for mechanistic research. For fat loss research, AOD-9604 provides the stronger evidence base, while HGH Fragment offers a simpler, more accessible option for basic research.
Medical Disclaimer
The information provided in this comparison is for educational and research purposes only. Neither AOD-9604 nor HGH Fragment 176-191 is approved for human therapeutic use by the MHRA, EMA, or FDA. This content does not constitute medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement.